Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Name: Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
License: Public Domain

Providence Health & Services

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

braf np_004324.2:p.v600m, braf v600e mutation present, metastatic thyroid gland carcinoma, refractory thyroid gland carcinoma, stage iv differentiated thyroid gland carcinoma ajcc v8, stage iva differentiated thyroid gland carcinoma ajcc v8

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 125849
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.